- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07858903
Initial Safety and Preliminary Efficacy of the Novelrad Vascular Closure System (NVCS)
A First in Human (FIH) Clinical Study to Evaluate the Initial Safety and Preliminary Efficacy of the Suture-Mediated Novelrad Vascular Closure System
This study evaluates the initial safety and preliminary efficacy of the Novelrad Vascular Closure System (NVCS), a suture-mediated vascular closure system, in achieving post-procedure hemostasis in subjects undergoing interventional catheterization procedures through the common femoral artery using large-bore procedural sheaths.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The Novelrad Vascular Closure System (NVCS) is an investigational suture-mediated vascular closure device intended for use following percutaneous interventional catheterization procedures performed through the common femoral artery using large-bore procedural sheaths. The NVCS is designed to facilitate percutaneous closure of the arteriotomy using a continuous suture technique.
The study is being conducted to evaluate the initial safety and preliminary efficacy of the NVCS in subjects undergoing percutaneous interventional catheterization procedures using large-bore procedural sheaths.
Type d'étude
Inscription (Réel)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Jerusalem, Israël
- Hadassah Medical Center
-
Jerusalem, Israël
- Shaare Zedek Medical Center
-
Tel Aviv, Israël
- Sourasky Tel-Aviv Medical Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Subject is ≥18 years old.
- Subject is scheduled for elective or planned (i.e., not emergent or urgent) percutaneous transcatheter interventional procedures involving access through the femoral artery using 8-22 French introducer sheaths such as TAVI/TAVR/EVAR/TEVAR etc.
- Subject has suitable sized vessel / calcification as evaluated on pre-procedural CT angiography by the investigator and by the study' screening committee
- Subject is able to undergo emergent vascular surgery if a complication related to the vascular closure necessitates such surgery
- Understand and sign the study specific written informed consent form
- Able and willing to fulfill the follow-up requirements
Exclusion Criteria:
Baseline Exclusions:
- Known to be pregnant or lactating.
- Immunocompromised or with pre-existing autoimmune disease.
- Systemic infection or a local infection at or near the access site.
- Significant anemia (Hgb < 9 g/dL hematocrit <30%).
- Morbidly obese or cachectic (BMI >40 kg/m2 or <20kg/m2).
- Known bleeding disorders including thrombocytopenia (platelet count <100,000 cells/UL), thrombasthenia, hemophilia, von Willebrand disease, or hypercoagulability.
- Known allergy to any device component.
- Femoral artery puncture in target groin within the prior 14 days, recent femoral artery puncture in target groin that has not healed appropriately, and/or prior vascular closure device placement in target common femoral artery that the investigator determines may interfere with the NVCS.
- Common femoral artery with calcium, as determined by baseline CTA, precluding safe access in the opinion of the investigator or severe peripheral vascular disease as evidenced by severe claudication when ambulating < 30 meter, weak or absent pulses in the affected limb.
- Previous intervention in region of access site, including but not limited to prior atherectomy, stenting, surgical or grafting procedures in the access area.
- Prior target artery closure with any closure device < 180 days, or closure with manual compression ≤ 90 days prior to index procedure.
- Subjects who have undergone use of an intra-aortic balloon pump through the arterial access site.
- Undergoing therapeutic thrombolysis.
- Subjects in whom oral anticoagulation therapy cannot be stopped for the peri-procedural period or subjects with INR >1.8 at the time of the procedure.
- Subject unable to be adequately anti-coagulated for the procedure.
- Subjects who are not mobile and are confined to a wheelchair or bed.
- ST-elevation MI within 45 days prior to procedure or acute coronary syndrome (i.e., unstable angina or myocardial infarction) ≤14 days before the catheterization procedure
- NYHA class IV heart failure.
- Left ventricular ejection fraction <20%.
- Unilateral or bilateral lower extremity amputation.
- Renal insufficiency (serum creatinine >2.5 mg/dl) or on dialysis therapy, or after renal transplant.
- Existing nerve damage in the NVCS treated leg.
- Further planned endovascular procedure within the next 30 days.
- Subjects currently participating in another clinical study of an unapproved investigational device or drug that has not concluded the follow-up period.
- Subject cannot adhere to or complete the investigational protocol for any reason including but not limited to geographical residence, psychiatric condition or life-threatening disease.
- Common femoral artery <6mm or >50% diameter femoral stenosis by baseline CTA and/or severe peripheral arterial disease or Rutherford Classification 5 or 6.
- Planned anticoagulation therapy post-procedure such that the Activated Clotting Time (ACT) is expected to be elevated above 350 seconds for more than 24 hours after the procedure.
- Known severe allergy to contrast reagent that cannot be managed with premedication.
- Connective tissue disease (e.g., Marfan's Syndrome).
- Thrombolytics (e.g., streptokinase, urokinase), Angiomax (bivalirudin) or other thrombin-specific anticoagulants ≤ 24 hours prior to the procedure.
- Subject is mentally incompetent or a prisoner.
- Planned antegrade puncture during the index procedure.
- Stenosis >50% diameter of access site's ipsilateral iliac artery that the investigator determines may interfere with the NVCS.
- Subject unable to ambulate at baseline (i.e., confined to wheelchair or bed).
Intra-Procedure Exclusions:
- On baseline Duplex US the Common femoral artery <6mm or >50% stenosis of the femoral artery.
- Puncture site took place in the profunda femoris artery, superficial femoral artery, or at the bifurcation of these arteries or if less than one third of the access needle is above the skin line indicating the subject is morbidly obese.
- Common femoral artery suspected to have experienced a back wall puncture or underwent > one (1) arterial puncture during the catheterization procedure.
- Difficult dilation from initial femoral artery access (e.g., damaging or kinking dilators) while step dilating up to the large-bore device.
- Actual puncture site located above the most inferior border of the epigastric artery (IEA) and/or above the inguinal ligament based upon bony landmarks.
- Marked tortuosity of femoral or iliac artery that to the opinion of the user prohibiting the use of the device.
- Systolic blood pressure >180 mmHg or diastolic blood pressure >110 mm Hg, unless systolic or diastolic pressure can be lowered by pharmacological agents prior to closure.
- Planned antegrade puncture during the index procedure.
- Possible bacterial contamination of the procedure's sheath or surrounding tissues during the procedure.
- Intra-procedural complication(s) at the femoral access site before procedural sheath removal and before sliding the NVCS knot down, including: 1. Bleeding or swelling around the sheath that may indicate hematoma formation and/or pseudoaneurysm formation; and 2. Peri-procedural duplex us/angiographic evidence of thrombus formation or significant injury in the aorta or iliac vessels associated with procedural large bore sheath placement and/or sub-optimal anticoagulation.
- Presence of ipsilateral femoral venous sheath during the interventional procedure.
- Systolic blood pressure <90 mm Hg just prior to planned vascular closure without the ability to increase it.
- Planned anticoagulation therapy post-procedure such that the Activated Clotting Time (ACT) is expected to be elevated above 350 seconds for more than 24 hours after the procedure.
- Index procedure planned sheath or interventional device >22Fr during the procedure.
- Evidence of a pre-existing hematoma (> 1.5 cm in diameter), arteriovenous fistula, pseudoaneurysm, or intraluminal thrombosis at the access site before insertion of the NVCS.
- Duplex US (or by angiography if applicable) evidence of arterial laceration, dissection, or stenosis in the femoral artery that would preclude use of the device.
- Stenosis >50% diameter of access site's ipsilateral iliac artery that the investigator determines may interfere with the NVCS.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Novelrad Vascular Closure System (NVCS)
The Novelrad Vascular Closure System (NVCS), will be used in subjects who are undergoing diagnostic or interventional catheterization procedures |
NVCS will be used to close the common femoral artery access site while reducing time-to-hemostasis in subjects who have undergone diagnostic or interventional catheterization procedures using 8-22 French (F) Sheaths. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Safety: Freedom from major complications of the target limb within 30 days following the procedure
Délai: Within 30 days post-procedure
|
Assessment of the incidence of protocol defined major complications of the target limb access site through 30 days post procedure as specified in the protocol. |
Within 30 days post-procedure
|
|
Efficacy: Mean Time to Hemostasis
Délai: Periprocedural
|
The Time to Hemostasis is defined as the elapsed time between withdrawal of index procedure sheath from common femoral artery and first observed and confirmed arterial hemostasis (no or minimal subcutaneous oozing and the absence of expanding or developing hematoma). |
Periprocedural
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Safety: Frequency of minor complications at the target limb.
Délai: Within 30 days post procedure
|
Assessment of the incidence of minor complications of the target limb access site as specified in the protocol. |
Within 30 days post procedure
|
|
Efficacy: Technical Success
Délai: Periprocedural
|
Achievement of hemostasis with the NVCS without the need for any access-site-related adjunctive surgical or endovascular intervention (target limb only). |
Periprocedural
|
|
Efficacy: Treatment/Procedure Success
Délai: Within 30 days post procedure
|
Subjects with technical success and free from major complications through 30 days follow-up. |
Within 30 days post procedure
|
|
Efficacy: Mean Time for NVCS Procedure
Délai: Periprocedural
|
The elapsed time from initial skin break (first needle insertion) to time when the suture is released from the NVCD plus the elapsed time from performing the knot at the end of the index procedure and until hemostasis is achieved. |
Periprocedural
|
|
Efficacy: Mean Time to Ambulation
Délai: Within 24 hours after procedural sheath removal
|
The elapsed time between last procedural sheath removal and when ambulation is achieved (subject is standing and walking at least 6-meters without bleeding). |
Within 24 hours after procedural sheath removal
|
|
Time-to-discharge eligibility
Délai: Within 48 hours after the procedure
|
The time following the removal of the NVCS and when the patient is eligible for discharge based solely on (1) completion TTA, (2) freedom from orthostatic hypotension [defined as stable blood pressure and heart rate after ambulating], (3) ability to void and, (4) a stable access site without bleeding or expansion of a prior hematoma. |
Within 48 hours after the procedure
|
|
Efficacy: Percent of subjects with surgical or endovascular intervention post closure
Délai: Periprocedural
|
Subjects require adjunctive surgical or endovascular intervention to achieve hemostasis of the NVCS access site. |
Periprocedural
|
|
Efficacy: Percent of subjects with NVCS Failure
Délai: Periprocedural
|
When the device is used in accordance with the IFU, but does not perform as described in the IFU, and/or negatively impacts treatment of the study subject. |
Periprocedural
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Yossi Muncher, Ph.D., Novelrad Ltd.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- NVCS-CLN-001
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .